Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Interactive Tools
Sponsored
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Optimizing Treatment Strategies in R/R Hepatocellular Carcinoma - Episode 5
Transitioning From Locoregional to Systemic Therapy
June 29, 2020
Peter R. Galle, MD, PhD, Mainz University Medical Center
,
Minsig Choi, MD, Stony Brook University Hospital
,
Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine
,
Kate Kelley, MD, UCSF Health
EP. 1: HCC Etiologic Risk Factors and Global Prevalence
EP. 2: HCC Global Screening Programs for At-Risk Populations
EP. 3: The Evolving Role of Medical Oncologists and Hepatologists
EP. 4: HCC Diagnosis and Prognosis
Now Viewing
EP. 5: Transitioning From Locoregional to Systemic Therapy
EP. 6: HCC Treatment Algorithm: Asia and Europe
EP. 7: Frontline Decision Factors for Metastatic Disease
EP. 8: Phase 3 IMbrave150 Trial
EP. 9: Frontline Therapy: Promising I/O Combinations
EP. 10: Frontline I/O: Clinical Trial Overviews
EP. 11: R/R HCC: Second-Line Options
EP. 12: Second-Line Sequencing After IMbrave150 Regimen
EP. 13: Second-Line Therapy: Monoclonal Antibody
EP. 14: REACH and REACH2 Trial Overview
EP. 15: I/O Second-Line Treatment
EP. 16: Metastatic HCC Unmet Needs
EP. 17: Emerging Therapies for HCC Management
Related Content:
Optimizing Treatment Strategies in R/R Hepatocellular Carcinoma
Emerging Therapies for HCC Management
Metastatic HCC Unmet Needs
I/O Second-Line Treatment
